Use of Diagnostic Algorithms for *NTRK* Fusion-Positive Tumors in Pathology Institutes in Switzerland
In May 2020, larotrectinib (Vitrakvi^®^) was approved as the first tumor-agnostic agent in Switzerland for the treatment of adult and pediatric patients with solid tumors that have a neurotrophic tyrosine receptor kinase (*NTRK*) gene fusion. While in certain types of tumors an *NTRK* gene fusion is...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
THE HEALTHBOOK COMPANY LTD.
2021-03-01
|
| Series: | healthbook TIMES. Oncology Hematology |
| Online Access: | https://doi.org/10.36000/hbT.OH.2021.07.030 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|